Sign Up

Sign Up to our social questions and Answers Engine to ask questions, answer people’s questions, and connect with other people.

Have an account? Sign In


Have an account? Sign In Now

Sign In

Login to our social questions & Answers Engine to ask questions answer people’s questions & connect with other people.

Sign Up Here


Forgot Password?

Don't have account, Sign Up Here

Forgot Password

Lost your password? Please enter your email address. You will receive a link and will create a new password via email.


Have an account? Sign In Now

You must login to ask a question.


Forgot Password?

Need An Account, Sign Up Here

You must login to add post.


Forgot Password?

Need An Account, Sign Up Here
Sign InSign Up

Qaskme

Qaskme Logo Qaskme Logo

Qaskme Navigation

  • Home
  • Questions Feed
  • Communities
  • Blog
Search
Ask A Question

Mobile menu

Close
Ask A Question
  • Home
  • Questions Feed
  • Communities
  • Blog
Home/healthcare ai
  • Recent Questions
  • Most Answered
  • Answers
  • No Answers
  • Most Visited
  • Most Voted
  • Random
daniyasiddiquiEditor’s Choice
Asked: 27/11/2025In: Technology

What governance frameworks are needed to manage high-risk AI systems (healthcare, finance, public services)?

governance frameworks are needed to m ...

ai regulationai-governancefinance aihealthcare aihigh-risk aipublic sector ai
  1. daniyasiddiqui
    daniyasiddiqui Editor’s Choice
    Added an answer on 27/11/2025 at 2:34 pm

    Core components of an effective governance framework 1) Legal & regulatory compliance layer Why: High-risk AI is already subject to specific legal duties (e.g., EU AI Act classification and obligations for “high-risk” systems; FDA expectations for AI in medical devices; financial regulators’ scrRead more

    Core components of an effective governance framework

    1) Legal & regulatory compliance layer

    Why: High-risk AI is already subject to specific legal duties (e.g., EU AI Act classification and obligations for “high-risk” systems; FDA expectations for AI in medical devices; financial regulators’ scrutiny of model risk). Compliance is the floor not the ceiling.

    What to put in place

    • Regulatory mapping: maintain an authoritative register of applicable laws, standards, and timelines (EU AI Act, local medical device rules, financial supervisory guidance, data protection laws).

    • Pre-market approvals / conformity assessments where required.

    • Documentation to support regulatory submissions (technical documentation, risk assessments, performance evidence, clinical evaluation or model validation).

    • Regulatory change process to detect and react to new obligations.

    2) Organisational AI risk management system (AI-MS)

    Why: High-risk AI must be managed like other enterprise risks systematically and end-to-end. ISO/IEC 42001 provides a framework for an “AI management system” to institutionalise governance, continuous improvement, and accountability.

    What to put in place

    • Policy & scope: an enterprise AI policy defining acceptable uses, roles, and escalation paths.

    • Risk taxonomy: model risk, data risk, privacy, safety, reputational, systemic/financial.

    • Risk tolerance matrix and classification rules for “high-risk” vs. lower-risk deployments.

    • AI change control and release governance (predetermined change control is a best practice for continuously-learning systems). 

    3) Model lifecycle governance (technical + process controls)

    Why: Many harms originate from upstream data or lifecycle gaps poor training data, drift, or uncontrolled model changes.

    Key artifacts & controls

    • Data governance: lineage, provenance, quality checks, bias audits, synthetic data controls, and legal basis for use of personal data.

    • Model cards & datasheets: concise technical and usage documentation for each model (intended use, limits, dataset description, evaluation metrics).

    • Testing & validation: pre-deployment clinical/operational validation, stress testing, adversarial testing, and out-of-distribution detection.

    • Versioning & reproducibility: immutable model and dataset artefacts (fingerprints, hashes) and CI/CD pipelines for ML (MLOps).

    • Explainability & transparency: model explanations appropriate to the audience (technical, regulator, end user) and documentation of limitations.

    • Human-in-the-loop controls: defined human oversight points and fallbacks for automated actions.

    • Security & privacy engineering: robust access control, secrets management, secure model hosting, and privacy-preserving techniques (DP, federated approaches where needed).

    (These lifecycle controls are explicitly emphasised by health and safety regulators and by financial oversight bodies focused on model risk and explainability.) 

    4) Independent oversight, audit & assurance

    Why: Independent review reduces conflicts of interest, uncovers blind spots, and builds stakeholder trust.

    What to implement

    • AI oversight board or ethics committee with domain experts (clinical leads, risk, legal, data science, external ethicists).

    • Regular internal audits and third-party audits focused on compliance, fairness, and safety.

    • External transparency mechanisms (summaries for the public, redacted technical briefs to regulators).

    • Certification or conformance checks against recognised standards (ISO, sector checklists).

    5) Operational monitoring, incident response & continuous assurance

    Why: Models degrade, data distributions change, and new threats emerge governance must be dynamic.

    Practical measures

    • Production monitoring: performance metrics, drift detection, bias monitors, usage logs, and alert thresholds.

    • Incident response playbook: roles, communications, rollback procedures, root cause analysis, and regulatory notification templates.

    • Periodic re-validation cadence and triggers (performance fall below threshold, significant data shift, model changes).

    • Penetration testing and red-team exercises for adversarial risks.

    6) Vendor & third-party governance

    Why: Organisations increasingly rely on pre-trained models and cloud providers; third-party risk is material.

    Controls

    • Contractual clauses: data use restrictions, model provenance, audit rights, SLAs for security and availability.

    • Vendor assessments: security posture, model documentation, known limitations, patching processes.

    • Supply-chain mapping: dependencies on sub-vendors and open source components.

    7) Stakeholder engagement & ethical safeguards

    Why: Governance must reflect societal values, vulnerable populations’ protection, and end-user acceptability.

    Actions

    • Co-design with clinical users or citizen representatives for public services.

    • Clear user notices, consent flows, and opt-outs where appropriate.

    • Mechanisms for appeals and human review of high-impact decisions.

    (WHO’s guidance for AI in health stresses ethics, equity, and human rights as central to governance.) 

    Operational checklist (what to deliver first 90 days)

    1. Regulatory & standards register (live). 

    2. AI policy & classification rules for high risk.

    3. Model inventory with model cards and data lineage.

    4. Pre-deployment validation checklist and rollback plan.

    5. Monitoring dashboard: performance + drift + anomalies.

    6. Vendor risk baseline + standard contractual templates.

    7. Oversight committee charter and audit schedule.

    Roles & responsibilities (recommended)

    • Chief AI Risk Officer / Head of AI Governance: accountable for framework, reporting to board.

    • Model Owner/Business Owner: defines intended use, acceptance criteria.

    • ML Engineers / Data Scientists: implement lifecycle controls, reproducibility.

    • Clinical / Domain Expert: validates real-world clinical/financial suitability.

    • Security & Privacy Officer: controls access, privacy risk mitigation.

    • Internal Audit / Independent Reviewer: periodic independent checks.

    Metrics & KPIs to track

    • Percentage of high-risk models with current validation within X months.

    • Mean time to detect / remediate model incidents.

    • Drift rate and performance drop thresholds.

    • Audit findings closed vs open.

    • Number of regulatory submissions / actions pending.

    Final, humanized note

    Governance for high-risk AI is not a single document you file and forget. It is an operating capability a mix of policy, engineering, oversight, and culture. Start by mapping risk to concrete controls (data quality, human oversight, validation, monitoring), align those controls to regulatory requirements (EU AI Act, medical device frameworks, financial supervisory guidance), and institutionalise continuous assurance through audits and monitoring. Standards like ISO/IEC 42001, sector guidance from WHO/FDA, and international principles (OECD) give a reliable blueprint; the job is translating those blueprints into operational artefacts your teams use every day. 

    See less
      • 0
    • Share
      Share
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share on WhatsApp
  • 0
  • 1
  • 112
  • 0
Answer
daniyasiddiquiEditor’s Choice
Asked: 19/11/2025In: Digital health

How can generative AI/large-language-models (LLMs) be safely and effectively integrated into clinical workflows (e.g., documentation, triage, decision support)?

generative AI/large-language-models ( ...

clinical workflowsgenerative-aihealthcare ailarge language models (llms)medical documentationtriage
  1. daniyasiddiqui
    daniyasiddiqui Editor’s Choice
    Added an answer on 19/11/2025 at 4:01 pm

    1) Why LLMs are different and why they help LLMs are general-purpose language engines that can summarize notes, draft discharge letters, translate clinical jargon to patient-friendly language, triage symptom descriptions, and surface relevant guidelines. Early real-world studies show measurable timeRead more

    1) Why LLMs are different and why they help

    LLMs are general-purpose language engines that can summarize notes, draft discharge letters, translate clinical jargon to patient-friendly language, triage symptom descriptions, and surface relevant guidelines. Early real-world studies show measurable time savings and quality improvements for documentation tasks when clinicians edit LLM drafts rather than writing from scratch. 

    But because LLMs can also “hallucinate” (produce plausible-sounding but incorrect statements) and echo biases from their training data, clinical deployments must be engineered differently from ordinary consumer chatbots. Global health agencies emphasize risk-based governance and stepwise validation before clinical use.

    2) Overarching safety principles (short list you’ll use every day)

    1. Human-in-the-loop (HITL) : clinicians must review and accept all model outputs that affect patient care. LLMs should assist, not replace, clinical judgment.

    2. Risk-based classification & testing : treat high-impact outputs (diagnostic suggestions, prescriptions) with the strictest validation and possibly regulatory pathways; lower-risk outputs (note summarization) can follow incremental pilots. 

    3. Data minimization & consent : only send the minimum required patient data to a model and ensure lawful patient consent and audit trails. 

    4. Explainability & provenance : show clinicians why a model recommended something (sources, confidence, relevant patient context).

    5. Continuous monitoring & feedback loops : instrument for performance drift, bias, and safety incidents; retrain or tune based on real clinical feedback. 

    6. Privacy & security : encrypt data in transit and at rest; prefer on-prem or private-cloud models for PHI when feasible. 

    3) Practical patterns for specific workflows

    A : Documentation & ambient scribing (notes, discharge summaries)

    Common use: transcribe/clean clinician-patient conversations, summarize, populate templates, and prepare discharge letters that clinicians then edit.

    How to do it safely:

    Use the audio→transcript→LLM pipeline where the speech-to-text module is tuned for medical vocabulary.

    • Add a structured template: capture diagnosis, meds, recommendations as discrete fields (FHIR resources like Condition, MedicationStatement, Plan) rather than only free text.

    • Present LLM outputs as editable suggestions with highlighted uncertain items (e.g., “suggested medication: enalapril confidence moderate; verify dose”).

    • Keep a clear provenance banner in the EMR: “Draft generated by AI on [date] clinician reviewed on [date].”

    • Use ambient scribe guidance (controls, opt-out, record retention). NHS England has published practical guidance for ambient scribing adoption that emphasizes governance, staff training, and vendor controls. 

    Evidence: randomized and comparative studies show LLM-assisted drafting can reduce documentation time and improve completeness when clinicians edit the draft rather than relying on it blindly. But results depend heavily on model tuning and workflow design.

    B: Triage and symptom checkers

    Use case: intake bots, tele-triage assistants, ED queue prioritization.

    How to do it safely:

    • Define clear scope and boundary conditions: what the triage bot can and cannot do (e.g., “This tool provides guidance if chest pain is present, call emergency services.”).

    • Embed rule-based safety nets for red flags that bypass the model (e.g., any mention of “severe bleeding,” “unconscious,” “severe shortness of breath” triggers immediate escalation).

    • Ensure the bot collects structured inputs (age, vitals, known comorbidities) and maps them to standardized triage outputs (e.g., FHIR TriageAssessment concept) to make downstream integration easier.

    • Log every interaction and provide an easy clinician review channel to adjust triage outcomes and feed corrections back into model updates.

    Caveat: triage decisions are high-impact many regulators and expert groups recommend cautious, validated trials and human oversight. treatment suggestions)

    Use case: differential diagnosis, guideline reminders, medication-interaction alerts.

    How to do it safely:

    • Limit scope to augmentative suggestions (e.g., “possible differential diagnoses to consider”) and always link to evidence (guidelines, primary literature, local formularies).

    • Versioned knowledge sources: tie recommendations to a specific guideline version (e.g., WHO, NICE, local clinical protocols) and show the citation.

    • Integrate with EHR alerts: thoughtfully avoid alert fatigue by prioritizing only clinically actionable, high-value alerts.

    • Clinical validation studies: before full deployment, run prospective studies comparing clinician performance with vs without the LLM assistant. Regulators expect structured validation for higher-risk applications. 

    4) Regulation, certification & standards you must know

    • WHO guidance : on ethics & governance for LMMs/AI in health recommends strong oversight, transparency, and risk management. Use it as a high-level checklist.

    • FDA: is actively shaping guidance for AI/ML in medical devices if the LLM output can change clinical management (e.g., diagnostic or therapeutic recommendations), engage regulatory counsel early; FDA has draft and finalized documents on lifecycle management and marketing submissions for AI devices.

    • Professional societies (e.g., ESMO, specialty colleges) and national health services are creating local guidance follow relevant specialty guidance and integrate it into your validation plan. 

    5) Bias, fairness, and equity  technical and social actions

    LLMs inherit biases from training data. In medicine, bias can mean worse outcomes for women, people of color, or under-represented languages.

    What to do:

    • Conduct intersectional evaluation (age, sex, ethnicity, language proficiency) during validation. Recent reporting shows certain AI tools underperform on women and ethnic minorities a reminder to test broadly. 

    • Use local fine-tuning with representative regional clinical data (while respecting privacy rules).

    • Maintain an incident register for model-related harms and run root-cause analyses when issues appear.

    • Include patient advocates and diverse clinicians in design/test phases.

    6) Deployment architecture & privacy choices

    Three mainstream deployment patterns choose based on risk and PHI sensitivity:

    1. On-prem / private cloud models : best for high-sensitivity PHI and stricter jurisdictions.

    2. Hosted + PHI minimization : send de-identified or minimal context to a hosted model; keep identifiers on-prem and link outputs with tokens.

    3. Hybrid edge + cloud : run lightweight inference near the user for latency and privacy, call bigger models for non-PHI summarization or second-opinion tasks.

    Always encrypt, maintain audit logs, and implement role-based access control. The FDA and WHO recommend lifecycle management and privacy-by-design. 

    7) Clinician workflows, UX & adoption

    • Build the model into existing clinician flows (the fewer clicks, the better), e.g., inline note suggestions inside the EMR rather than a separate app.

    • Display confidence bands and source links for each suggestion so clinicians can quickly judge reliability.

    • Provide an “explain” button that reveals which patient data points led to an output.

    • Run train-the-trainer sessions and simulation exercises using real (de-identified) cases. The NHS and other bodies emphasize staff readiness as a major adoption barrier. 

    8) Monitoring, validation & continuous improvement (operational playbook)

    1. Pre-deployment

      • Unit tests on edge cases and red flags.

      • Clinical validation: prospective or randomized comparative evaluation. 

      • Security & privacy audit.

    2. Deployment & immediate monitoring

      • Shadow mode for an initial period: run the model but don’t show outputs to clinicians; compare model outputs to clinician decisions.

      • Live mode with HITL and mandatory clinician confirmation.

    3. Ongoing

      • Track KPIs (see below).

      • Daily/weekly safety dashboards for hallucinations, mismatches, escalation events.

      • Periodic re-validation after model or data drift, or every X months depending on risk.

    9) KPIs & success metrics (examples)

    • Clinical safety: rate of clinically significant model errors per 1,000 uses.

    • Efficiency: median documentation time saved per clinician (minutes). 

    • Adoption: % of clinicians who accept >50% of model suggestions.

    • Patient outcomes: time to treatment, readmission rate changes (where relevant).

    • Bias & equity: model performance stratified by demographic groups.

    • Incidents: number and severity of model-related safety incidents.

    10) A templated rollout plan (practical, 6 steps)

    1. Use-case prioritization : pick low-risk, high-value tasks first (note drafting, coding, administrative triage).

    2. Technical design : choose deployment pattern (on-prem vs hosted), logging, API contracts (FHIR for structured outputs).

    3. Clinical validation : run prospective pilots with defined endpoints and safety monitoring. 

    4. Governance setup : form an AI oversight board with legal, clinical, security, patient-rep members. 

    5. Phased rollout : shadow → limited release with HITL → broader deployment.

    6. Continuous learning : instrument clinician feedback directly into model improvement cycles.

    11) Realistic limitations & red flags

    • Never expose raw patient identifiers to public LLM APIs without contractual and technical protections.

    • Don’t expect LLMs to replace structured clinical decision support or robust rule engines where determinism is required (e.g., dosing calculators).

    • Watch for over-reliance: clinicians may accept incorrect but plausible outputs if not trained to spot them. Design UI patterns to reduce blind trust.

    12) Closing practical checklist (copy/paste for your project plan)

    •  Identify primary use case and risk level.

    •  Map required data fields and FHIR resources.

    •  Decide deployment (on-prem / hybrid / hosted) and data flow diagrams.

    •  Build human-in-the-loop UI with provenance and confidence.

    •  Run prospective validation (efficiency + safety endpoints). 

    •  Establish governance body, incident reporting, and re-validation cadence. 

    13) Recommended reading & references (short)

    • WHO : Ethics and governance of artificial intelligence for health (guidance on LMMs).

    • FDA : draft & final guidance on AI/ML-enabled device lifecycle management and marketing submissions.

    • NHS : Guidance on use of AI-enabled ambient scribing in health and care settings. 

    • JAMA Network Open : real-world study of LLM assistant improving ED discharge documentation.

    • Systematic reviews on LLMs in healthcare and clinical workflow integration. 

    Final thought (humanized)

    Treat LLMs like a brilliant new colleague who’s eager to help but makes confident mistakes. Give them clear instructions, supervise their work, cross-check the high-stakes stuff, and continuously teach them from the real clinical context. Do that, and you’ll get faster notes, safer triage, and more time for human care while keeping patients safe and clinicians in control.

    See less
      • 0
    • Share
      Share
      • Share on Facebook
      • Share on Twitter
      • Share on LinkedIn
      • Share on WhatsApp
  • 0
  • 1
  • 126
  • 0
Answer

Sidebar

Ask A Question

Stats

  • Questions 548
  • Answers 1k
  • Posts 20
  • Best Answers 21
  • Popular
  • Answers
  • mohdanas

    Are AI video generat

    • 868 Answers
  • daniyasiddiqui

    “What lifestyle habi

    • 7 Answers
  • Anonymous

    Bluestone IPO vs Kal

    • 5 Answers
  • RobertMib
    RobertMib added an answer Кент казино позволяет начать игру сразу после регистрации. Процесс занимает несколько минут. Сайт работает стабильно. Игры загружаются быстро. Это удобно… 27/01/2026 at 8:24 am
  • tyri v piter_uiea
    tyri v piter_uiea added an answer питер экскурсионные туры [url=https://tury-v-piter.ru/]tury-v-piter.ru[/url] . 27/01/2026 at 8:01 am
  • tyri v piter_taea
    tyri v piter_taea added an answer туроператоры по санкт петербургу экскурсионные туры [url=https://tury-v-piter.ru/]tury-v-piter.ru[/url] . 27/01/2026 at 7:43 am

Top Members

Trending Tags

ai aiineducation ai in education analytics artificialintelligence artificial intelligence company deep learning digital health edtech education health investing machine learning machinelearning news people tariffs technology trade policy

Explore

  • Home
  • Add group
  • Groups page
  • Communities
  • Questions
    • New Questions
    • Trending Questions
    • Must read Questions
    • Hot Questions
  • Polls
  • Tags
  • Badges
  • Users
  • Help

© 2025 Qaskme. All Rights Reserved